{"id":"NCT01404312","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","briefTitle":"Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB)","officialTitle":"Phase III Clinical Trial of Ultra-Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-Infected Individuals With Latent Tuberculosis Infection","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-05-23","primaryCompletion":"2017-11-14","completion":"2017-11-14","firstPosted":"2011-07-28","resultsPosted":"2018-12-06","lastUpdate":"2021-11-04"},"enrollment":3000,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Tuberculosis","HIV Infections"],"interventions":[{"type":"DRUG","name":"Rifapentine (RPT)","otherNames":[]},{"type":"DRUG","name":"Isoniazid (INH)","otherNames":[]},{"type":"DIETARY_SUPPLEMENT","name":"Pyridoxine (Vitamin B6)","otherNames":[]}],"arms":[{"label":"RPT plus INH Regimen (Arm A)","type":"EXPERIMENTAL"},{"label":"INH Regimen (Arm B)","type":"ACTIVE_COMPARATOR"}],"summary":"HIV-infected people have an increased risk of developing active tuberculosis (TB). At the time the study was designed, the standard course of treatment for TB was 6 to 9 months of isoniazid (INH).This study compared the safety and effectiveness of a 4-week regimen of rifapentine (RPT) plus INH versus a standard 9-month regimen of INH in HIV-infected people who are at risk of developing active TB.","primaryOutcome":{"measure":"Incidence of First Diagnosis of Active Tuberculosis, Death Related to Tuberculosis, or Death From Unknown Cause","timeFrame":"From entry to occurrence of event, up to end of follow-up 3 years after last participant enrolled (median follow-up time: 3.3 years)","effectByArm":[{"arm":"RPT Plus INH Regimen (Arm A)","deltaMin":0.6506,"sd":null},{"arm":"INH Regimen (Arm B)","deltaMin":0.6736,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"13 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":13},"locations":{"siteCount":45,"countries":["United States","Botswana","Brazil","Haiti","Kenya","Malawi","Peru","South Africa","Thailand","Zimbabwe"]},"refs":{"pmids":["19525621","19729664","35943252","32815870","31414121","30865794","26082504"],"seeAlso":["https://rsc.niaid.nih.gov/sites/default/files/table-for-grading-severity-of-adult-pediatric-adverse-events.pdf","http://rsc.tech-res.com/docs/default-source/safety/manual_for_expedited_reporting_aes_to_daids_v2.pdf?sfvrsn=12"]},"adverseEventsSummary":{"seriousAny":{"events":40,"n":1496},"commonTop":["Cough","Blood sodium decreased","Pyrexia","Oropharyngeal pain","Neutrophil count decreased"]}}